Pembrolizumab: tested in a combination

521 studies: another drug in the study is under test too. Page 1 of 6. Open to participants first (187), then studies with results posted, then the rest; newest registration first within each.

• Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck CancerNot yet recruitingNCT07932067Phase 2Report a problem
• Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerRecruitingNCT07908979Phase 2Report a problem
• Neoadjuvant Pembrolizumab in Patients With High Risk, Stage IIB/IIC Cutaneous Melanoma: a Single Arm Proof of Concept Phase IIA Study.Not yet recruitingNCT07883759Phase 2Report a problem
• A Study of Treatment Delivery Preference In People With Kidney CancerRecruitingNCT07872553Phase 4Report a problem
• Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial CancerRecruitingNCT07867002Phase 3Report a problem
• A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor MonotherapyNot yet recruitingNCT07843550Phase 1/2Report a problem
• Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07840001Phase 2Report a problem
• A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerNot yet recruitingNCT07822373Phase 2Report a problem
• Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant MelanomaNot yet recruitingNCT07817901Phase 1/2Report a problem
• A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene TranslocationRecruitingNCT07809256Phase 3Report a problem
• Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive CholangiocarcinomaRecruitingNCT07786766Phase 2Report a problem
• Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBCNot yet recruitingNCT07786428Phase 2Report a problem
• Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)RecruitingNCT07744698Phase 4Report a problem
• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)RecruitingNCT07743190Phase 2Report a problem
• NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) MelanomaRecruitingNCT07740941Phase 2Report a problem
• Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07733466Phase 2Report a problem
• Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell CancerNot yet recruitingNCT07680088Phase 2Report a problem
• Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBCNot yet recruitingNCT07663747Phase 2Report a problem
• Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical CancerRecruitingNCT07645625Phase 4Report a problem
• Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial CarcinomaNot yet recruitingNCT07643519Phase 2Report a problem
• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerRecruitingNCT07603856Phase 2Report a problem
• Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy MaintenanceRecruitingNCT07594015Phase 2Report a problem
• MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.RecruitingNCT07574047Phase 2Report a problem
• Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingNCT07572123Phase 2/3Report a problem
• Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingNCT07566156Phase 3Report a problem
• Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabRecruitingNCT07486817Phase 2Report a problem
• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingNCT07475806Phase 2Report a problem
• Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatmentNot yet recruitingNCT07460206Phase 2Report a problem
• Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaRecruitingNCT07422779Not applicableReport a problem
• Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNot yet recruitingNCT07420439Phase 2Report a problem
• Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 AmplificationRecruitingNCT07417501Phase 2Report a problem
• Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon CancerNot yet recruitingNCT07409844Phase 2Report a problem
• Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingNCT07407920Phase 2Report a problem
• Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix CancerNot yet recruitingNCT07368985Phase 2Report a problem
• Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsRecruitingNCT07360743Phase 2Report a problem
• The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder CancerNot yet recruitingNCT07346053Phase 3Report a problem
• Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingNCT07332351Phase 2Report a problem
• Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01RecruitingNCT07290894Phase 2Report a problem
• Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentRecruitingNCT07275216Phase 2Report a problem
• A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT07269158Phase 1/2Report a problem
• Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian CancerRecruitingNCT07261683Phase 2Report a problem
• Impact of Circadian Rhythm on ImmunotherapyRecruitingNCT07224971Phase 2Report a problem
• Patient Preference for Subcutaneous vs. Intravenous Immune TherapyRecruitingNCT07223424Phase 2Report a problem
• Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial CarcinomaRecruitingNCT07221942Phase 2Report a problem
• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingNCT07198074Phase 3Report a problem
• A Study of YL242 in Subjects With Advanced Solid TumorsRecruitingNCT07197827Phase 1/2Report a problem
• Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized TrialNot yet recruitingNCT07190027Phase 1/2Report a problem
• Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)RecruitingNCT07187778Phase 2Report a problem
• Circulating Tumor DNA Response In Urothelial CancerRecruitingNCT07183319Phase 2Report a problem
• Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care ImmunotherapiesRecruitingNCT07174453Phase 3Report a problem
• Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint BlockadeRecruitingNCT07130032Phase 2Report a problem
• Adjuvant Immunotherapy for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07067450Not applicableReport a problem
• Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruitingNCT07061977Phase 3Report a problem
• Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerRecruitingNCT07027124Phase 2Report a problem
• ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT07021989Phase 2Report a problem
• Head and Neck Cancer Study Project in the Geriatric PopulationRecruitingNCT06998069Phase 3Report a problem
• Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG TherapyRecruitingNCT06972615Phase 2Report a problem
• Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal CholangiocarcinomaRecruitingNCT06923475Phase 2/3Report a problem
• A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06894459Phase 2Report a problem
• This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung CancerRecruitingNCT06882174Phase 2Report a problem
• NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer PatientsRecruitingNCT06845319Phase 2Report a problem
• Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct AdenocarcinomaRecruitingNCT06831136Phase 2Report a problem
• A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)RecruitingNCT06822543Phase 2Report a problem
• PD-1 Inhibitors Maintenance for cHL Post-autoHCTRecruitingNCT06812858Phase 2Report a problem
• Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingNCT06809140Phase 2Report a problem
• Pembrolizumab and Pemetrexed for Progressive ChordomaRecruitingNCT06794645Phase 2Report a problem
• A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCCNot yet recruitingNCT06793761Phase 2Report a problem
• Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory MelanomaRecruitingNCT06771544Phase 2Report a problem
• Pembrolizumab in Combination with Flutamide Treatment for Recurrence / Metastasis HNSCCNot yet recruitingNCT06694350Phase 2Report a problem
• Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsRecruitingNCT06673628Phase 2Report a problem
• Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentRecruitingNCT06669572Phase 2Report a problem
• First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+TrodelvyRecruitingNCT06667167Phase 2Report a problem
• Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialRecruitingNCT06636734Phase 2Report a problem
• PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial CancerRecruitingNCT06549855Not applicableReport a problem
• A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerRecruitingNCT06545955Phase 3Report a problem
• Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingNCT06545682Phase 1Report a problem
• A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingNCT06524544Phase 3Report a problem
• Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal CancerRecruitingNCT06493019Phase 2Report a problem
• Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2Report a problem
• Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2Report a problem
• Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant MelanomaRecruitingNCT06488482Phase 3Report a problem
• A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLRecruitingNCT06484920Phase 2Report a problem
• Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via ITRecruitingNCT06483347Phase 2Report a problem
• Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via ITRecruitingNCT06482801Phase 2Report a problem
• A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced CancersRecruitingNCT06422403Phase 2Report a problem
• Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast CancerNot yet recruitingNCT06407310Phase 2Report a problem
• ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICIRecruitingNCT06388031Phase 2Report a problem
• Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 2Report a problem
• CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3Report a problem
• Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerRecruitingNCT06356155Phase 2Report a problem
• Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile CancerRecruitingNCT06353906Phase 2Report a problem
• Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast CancerRecruitingNCT06318897Phase 2Report a problem
• Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell CarcinomaRecruitingNCT06304350Phase 2Report a problem
• Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaRecruitingNCT06302569Phase 2Report a problem
• Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)RecruitingNCT06266338Phase 2Report a problem
• Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06230471Phase 2Report a problem
• Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT06211335Phase 1Report a problem
• Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaRecruitingNCT06211114Phase 2Report a problem
• Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCCRecruitingNCT06170710Phase 2Report a problem
• Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell LymphomaRecruitingNCT06160843Phase 2Report a problem

← Pembrolizumab